105 related articles for article (PubMed ID: 21404400)
1. Atropisomerism in the vaptan class of vasopressin receptor ligands: the active conformation recognized by the receptor.
Tabata H; Nakagomi J; Morizono D; Oshitari T; Takahashi H; Natsugari H
Angew Chem Int Ed Engl; 2011 Mar; 50(13):3075-9. PubMed ID: 21404400
[No Abstract] [Full Text] [Related]
2. Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.
Tabata H; Yoneda T; Oshitari T; Takahashi H; Natsugari H
J Med Chem; 2017 May; 60(10):4503-4509. PubMed ID: 28475329
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
5. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
[TBL] [Abstract][Full Text] [Related]
7. Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
Loison S; Cottet M; Orcel H; Adihou H; Rahmeh R; Lamarque L; Trinquet E; Kellenberger E; Hibert M; Durroux T; Mouillac B; Bonnet D
J Med Chem; 2012 Oct; 55(20):8588-602. PubMed ID: 22984902
[TBL] [Abstract][Full Text] [Related]
8. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
9. Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors.
Griebenow N; Flessner T; Buchmueller A; Raabe M; Bischoff H; Kolkhof P
Bioorg Med Chem Lett; 2011 Apr; 21(8):2554-8. PubMed ID: 21396815
[TBL] [Abstract][Full Text] [Related]
10. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.
Molinari AJ; Trybulski EJ; Bagli J; Croce S; Considine J; Qi J; Ali K; Demaio W; Lihotz L; Cochran D
Bioorg Med Chem Lett; 2007 Nov; 17(21):5796-800. PubMed ID: 17855087
[TBL] [Abstract][Full Text] [Related]
11. A flexible approach for the preparation of substituted benzazepines: application to the synthesis of tolvaptan.
Cordero-Vargas A; Quiclet-Sire B; Zard SZ
Bioorg Med Chem; 2006 Sep; 14(18):6165-73. PubMed ID: 16782344
[TBL] [Abstract][Full Text] [Related]
12. Conivaptan Yamanouchi.
Doggrell SA
Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
[TBL] [Abstract][Full Text] [Related]
13. N-benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: insight into the active stereochemistry around the seven-membered ring.
Yoneda T; Tabata H; Tasaka T; Oshitari T; Takahashi H; Natsugari H
J Med Chem; 2015 Apr; 58(7):3268-73. PubMed ID: 25774991
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
[TBL] [Abstract][Full Text] [Related]
15. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.
Campiani G; Butini S; Fattorusso C; Trotta F; Gemma S; Catalanotti B; Nacci V; Fiorini I; Cagnotto A; Mereghetti I; Mennini T; Minetti P; Di Cesare MA; Stasi MA; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2005 Mar; 48(6):1705-8. PubMed ID: 15771414
[TBL] [Abstract][Full Text] [Related]
16. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
[TBL] [Abstract][Full Text] [Related]
17. Conformation analyses, dynamic behavior and amide bond distortions of medium-sized heterocycles. 1. Partially and fully reduced 1-benzazepines.
Qadir M; Cobb J; Sheldrake PW; Whittall N; White AJ; Hii KK; Horton PN; Hursthouse MB
J Org Chem; 2005 Mar; 70(5):1545-51. PubMed ID: 15730272
[TBL] [Abstract][Full Text] [Related]
18. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
[TBL] [Abstract][Full Text] [Related]
19. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
20. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
Slusarz MJ; Slusarz R; Ciarkowski J
Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
